Prognostic Value of the Expression of p53 and bcl-2 in Non-Small Cell Lung Cancer.
10.4046/trd.1998.45.5.962
- Author:
Seok Chul YANG
1
;
Ho Joo YOON
;
Dong Ho SHIN
;
Sung Soo PARK
;
Jung Hee LEE
;
Joo Seob KEUN
;
Gu KONG
;
Jung Dal LEE
Author Information
1. Department of Internal Medicine, College of Medicine, Hanyang University, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Non-small cell lung cancer;
Survival;
p53;
bcl-2
- MeSH:
Antibodies, Monoclonal;
Apoptosis;
Biomarkers;
Carcinogenesis;
Carcinoma, Non-Small-Cell Lung*;
Classification;
Follow-Up Studies;
Genes, Tumor Suppressor;
Humans;
Lung;
Lung Neoplasms;
Prognosis
- From:Tuberculosis and Respiratory Diseases
1998;45(5):962-974
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Alteration of p53 tumor suppressor genes is most frequently identified in human neoplasms, including lung carcinoma. It is well known that bcl-2 oncoprotein protects eel]s from apoptosis. Recent studies have demonstrated that bcl-2 expression is associated with favorable prognosis for patients with non-small cell lung carcinoma. However, the precise biologic role of bcl-2 in the development of these tumors is sri]1 obscure. p53 and bcl-2 have important regulatory influence in the apoptotic pathway and thus their relationship is of interest in tumorigenesis, especially lung cancer. Purpose : The author investigated to know the prognostic significance of the expression of p53 and bcl-2 in radically resected non-small cell lung cancer. Method : 84 cases of formalin-fixed paraffin-embedded blocks from resected primary non-small cell lung cancer from 1980 to 1994 at Hanyang University Hospital were available for both clinical follow-up and immunohistochemical staining using monoclonal antibodies for p53 and bcl-2. RESULTS: The histologic classification of the tumor was based on WHO criteria, and the specimens included 45 squamous cell carcinomas(53.6%), 28 adeonocarcinomas(33.3%) and 11 large cell carcinomas(13.1%). p53 immunoreactivity was noted in 47 cases of 84 cases (56.0%). bcl-2 immunoreactivity was noted in 15 cases of 84 cases (17.9%). The mean survival duration was 64.23 +/- 10.73 months in bcl-2 positive group and 35.28 +/- 4.39 months in bcl-2 negative group. The bcl-2 expression was significantly correlated with survival in radically resected non-small cell lung cancer patients(p=0.03). The mean survival duration was 34.71 +/- 6.12 months in p53 positive group and 45.35 +/- 6.30 months in p53 negative group(p=0.21). The p53 expression was not predictive for survival. There was no correlation between combination of the different status of p53 and bcl-2pression in our study. CONCLUSIONS: The interaction and the regulation of new biologic markers, such as those involved in the apoptotic pathway, are complex. bcl-2 overexpression is a good prognostic factor in non-small cell lung cancer and p53 expression is not significantly associated with the prognostic factor in non-small co]1 lung cancer.
